In gemcitabine‐resistant patient‐derived xenograft models of pancreatic cancer, acquired gemcitabine resistance was efficiently overcome by a pan‐HER antibody mixture, which was a cocktail of anti‐EGFR, anti‐HER2, and anti‐HER3 antibodies. This evidence concerns the gene EGFR and familial pancreatic carcinoma.